These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3866236)

  • 1. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets.
    Stearns ME; Jenkins DP; Tew KD
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8483-7. PubMed ID: 3866236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A time study on the uptake of estramustine into prostatic tumour 1013L cells in vitro.
    Kruse E; Hartley-Asp B
    Biochem Pharmacol; 1989 Feb; 38(4):702-4. PubMed ID: 2917024
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME; Tew KD
    Cancer Res; 1985 Aug; 45(8):3891-7. PubMed ID: 4016756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake, metabolism and antiproliferative effect of estramustine phosphate in human glioma cell lines.
    von Schoultz E; Gunnarsson PO; Henriksson R
    Anticancer Res; 1989; 9(6):1713-6. PubMed ID: 2697186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3.
    Hartley-Asp B
    Prostate; 1984; 5(1):93-100. PubMed ID: 6694918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estramustine. Metabolic pattern and possible mechanisms for its action in prostate cancer.
    Kadohama N; Kirdani RY; Madajewicz S; Murphy GP; Sandberg AA
    N Y State J Med; 1979 Jun; 79(7):1005-9. PubMed ID: 287893
    [No Abstract]   [Full Text] [Related]  

  • 7. Estramustine phosphate: metabolic aspects related to its action in prostatic cancer.
    Kadohama N; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1978 Feb; 119(2):234-9. PubMed ID: 633484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine.
    Tew KD; Woodworth A; Stearns ME
    Cancer Treat Rep; 1986 Jun; 70(6):715-20. PubMed ID: 3731136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer.
    Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H
    Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of cytotoxic steroids for prostate cancer.
    Petrow V; Padilla GM
    Prostate; 1986; 9(2):169-82. PubMed ID: 3748896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.
    Tew KD; Stearns ME
    Urol Res; 1987; 15(3):155-60. PubMed ID: 3307087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.
    Stearns ME; Wang M; Tew KD; Binder LI
    J Cell Biol; 1988 Dec; 107(6 Pt 2):2647-56. PubMed ID: 3060470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
    Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific binding of estramustine to prostatic proteins.
    Forsgren B; Björk P
    Urology; 1984 Jun; 23(6 Suppl):34-8. PubMed ID: 6375077
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.
    Björk P; Forsgren B; Gustafsson JA; Pousette A; Högberg B
    Cancer Res; 1982 May; 42(5):1935-42. PubMed ID: 7066904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.
    Gunnarsson PO; Andersson SB; Johansson SA; Nilsson T; Plym-Forshell G
    Eur J Clin Pharmacol; 1984; 26(1):113-9. PubMed ID: 6714283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and metabolism of estramustine in the Dunning R3327H tumour.
    Kruse E; Hartley-Asp B
    In Vivo; 1988; 2(6):371-5. PubMed ID: 2979955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of estramustine, a nitrogen mustard derivative of estradiol-17 beta, in cytosol from rat ventral prostate.
    Forsgren B; Högberg B; Gustafsson JA; Pousette A
    Acta Pharm Suec; 1978; 15(1):23-32. PubMed ID: 645366
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition by estramustine phosphate on estradiol and androgen binding in benign and malignant prostate in humans.
    Nilsson I; Liskowski L; Nilsson T
    Urology; 1976 Aug; 8(2):118-21. PubMed ID: 60819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.